DUGGAN ROBERT W 4
4 · Summit Therapeutics Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Summit Therapeutics CEO Robert Duggan Buys 100,000 Shares
What Happened
Robert W. Duggan, CEO of Summit Therapeutics (SMMT), reported a purchase of 100,000 shares on June 4, 2026. The shares were acquired at $14.60 per share for a total reported value of $1,460,000. The transaction is reported under code “P” (purchase) and is listed as an open market or private purchase.
Key Details
- Transaction date: 2026-06-04; Price: $14.60 per share; Shares: 100,000; Total value: $1,460,000.
- Transaction type: Purchase (code P) — reported as open market/private purchase.
- Shares owned after transaction: Not specified in the provided filing.
- Footnote: The filing includes a disclaimer (F1) where the reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
- Filing timeliness: The Form 4 was filed with the same date as the reported transaction (no late filing indicated in the provided data).
Context
Purchases by a company insider are commonly viewed as a stronger disclosure signal than sales because they require personal cash outlay; this report documents a cash purchase rather than an option exercise or award. The footnote clarifies the reporting person’s limited claimed beneficial ownership; it does not by itself explain the ownership structure or motivation for the purchase.
Insider Transaction Report
- Purchase
Common Stock
[F1]2026-06-04$14.60/sh+100,000$1,460,000→ 25,824,474 total(indirect: By Trust)
- 570,073,879
Common Stock
- 76,680(indirect: By Spouse)
Common Stock
[F1] - 31,000(indirect: By Spouse)
Common Stock
[F1] - 10,199,776(indirect: By Trust)
Common Stock
[F1]
Footnotes (1)
- [F1]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.